Description
Developer of Selective Intracrine Modulators (SIMs) designed for the treatment of cancer. The company develops Selective Intracrine Modulators to block the local formation of steroid hormones in hormone-dependent malignancies of the prostate, breast, and endometrium, benefitting patients with castration-resistant prostate cancer (CRPC).
Contact Information
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Trevor Penning Ph.D | Founder |